Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.77 |
| ▸ | TK2 | O00142 | 2/20 | 0.55 |
| ▸ | CDA | P32320 | 1/20 | 0.47 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.47 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.46 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL368853 | 1.00 | PYGM (0.77) | PYGMTK2CDASLC28A1SLC28A2 | |
| SCHEMBL4601745 | 1.00 | PYGM (0.77) | PYGMTK2CDASLC28A1SLC28A2 | |
| SCHEMBL12642313 | 1.00 | PYGM (0.77) | PYGMTK2CDASLC28A1SLC28A2 | |
| SCHEMBL6820491 | 0.90 | PYGM (0.77) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL6820494 | 0.90 | PYGM (0.77) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL6820485 | 0.90 | PYGM (0.77) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL158910 | 0.88 | PYGM (0.97) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL6758925 | 0.88 | PYGM (0.97) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL12143148 | 0.88 | PYGM (0.97) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL2579064 | 0.88 | PYGM (0.97) | PYGMTK2SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416293-A1 | SYNTHESIS OF [18F]-LABELED THYMIDINE ANALOGUES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-12-28 | — | — | US | claimed |
| WO-2022109244-A1 | SYNTHESIS OF [18F] -LABELED THYMIDINE ANALOGUES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-05-27 | — | — | WO | claimed |
| US-8912319-B2 | Synthesis of 2′-deoxy-2′-[18F]fluoro-5-methyl-1-B-D-arabinofuranosyluracil (18F-FMAU) | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2014-12-16 | — | — | US | claimed |
| EP-0010205-B1 | 5-SUBSTITUTED 1-(2'-DEOXY-2'-SUBSTITUTED-BETA-D-ARABINOFURANOSYL) PYRIMIDINE NUCLEOSIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Sloan-Kettering Institute For Cancer Research (US) | 1983-05-04 | — | — | EP | claimed |
| US-4211773-A | VIRICIDES, ANTITUMOR AGENTS | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1980-07-08 | — | — | US | claimed |
| EP-0010205-A1 | 5-Substituted 1-(2'-deoxy-2'-substituted-beta-D-arabinofuranosyl) pyrimidine nucleosides and pharmaceutical compositions containing them | Sloan-Kettering Institute For Cancer Research (US) | 1980-04-30 | — | — | EP | claimed |
| US-20230416293-A1 | SYNTHESIS OF [18F]-LABELED THYMIDINE ANALOGUES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-12-28 | — | — | US | disclosed |
| WO-2022109244-A1 | SYNTHESIS OF [18F] -LABELED THYMIDINE ANALOGUES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-05-27 | — | — | WO | disclosed |
| EP-2603516-B1 | SYNTHESIS OF 2'-DEOXY-2'-[18F]FLUORO-5-METHYL-1-B-D-ARABINOFURANOSYLURACIL (18F-FMAU) | UNIV SOUTHERN CALIFORNIA (US) | 2017-08-23 | — | — | EP | disclosed |
| US-8912319-B2 | Synthesis of 2′-deoxy-2′-[18F]fluoro-5-methyl-1-B-D-arabinofuranosyluracil (18F-FMAU) | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2014-12-16 | — | — | US | disclosed |
| US-20120053337-A1 | SYNTHESIS OF 2'-Deoxy-2'-[18F]FLUORO-5-METHYL-1-B-D-ARABINOFURANOSYLURACIL (18F-FMAU) | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-03-01 | — | — | US | disclosed |
| US-4594339-A | Veterinary medicine | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1986-06-10 | — | — | US | disclosed |
| EP-0010205-B1 | 5-SUBSTITUTED 1-(2'-DEOXY-2'-SUBSTITUTED-BETA-D-ARABINOFURANOSYL) PYRIMIDINE NUCLEOSIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Sloan-Kettering Institute For Cancer Research (US) | 1983-05-04 | — | — | EP | disclosed |
| US-4211773-A | VIRICIDES, ANTITUMOR AGENTS | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1980-07-08 | — | — | US | disclosed |
| EP-0010205-A1 | 5-Substituted 1-(2'-deoxy-2'-substituted-beta-D-arabinofuranosyl) pyrimidine nucleosides and pharmaceutical compositions containing them | Sloan-Kettering Institute For Cancer Research (US) | 1980-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416293-A1 | SYNTHESIS OF [18F]-LABELED THYMIDINE ANALOGUES | DCTD, DUT, RNMT | PYGM 3840/4885TK2 14/4885CDA 36/4885 |
| US-20120053337-A1 | SYNTHESIS OF 2'-Deoxy-2'-[18F]FLUORO-5-METHYL-1-B-D-ARABINOFURANOSYLURACIL (18F-FMAU) | CGAS, RNGTT, ADA | PYGM 395/4885TK2 99/4885CDA 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.